4-(2-(5-6-7-8-tetrahydro-5-5-8-8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic-acid has been researched along with Dermatitis* in 1 studies
1 other study(ies) available for 4-(2-(5-6-7-8-tetrahydro-5-5-8-8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic-acid and Dermatitis
Article | Year |
---|---|
Arotinoid acid (Ro 13-7410): a pilot study in dermatology.
Ro 13-7410 was given to 29 patients (a total of 38 treatment courses) for 7.5 weeks (range 4-23). This compound is one of the most potent retinoids ever synthetized and has the highest affinity to human skin cellular retinoic-acid-binding protein. At therapeutically active doses, it did not induce the commonly seen mucocutaneous signs of retinoid toxicity such as scaling and cheilitis; over 0.5 microgram/kg body weight/day, it very frequently induced an eczematous retinoid dermatitis. This pilot study provides some indications on what appears to be in several aspects a drug quite distinct from retinoids previously used in humans. Topics: Adult; Aged; Benzoates; Dermatitis; Female; Humans; Male; Middle Aged; Pilot Projects; Prurigo; Psoriasis; Retinoids; Skin Diseases | 1988 |